Director Converts $619K Preferred Stock to Common After Merger

summarizeSummary

Director Stephen M. Hahn converted $619,968 worth of preferred stock, obtained from the recent Faeth merger, into common stock, significantly increasing his direct common share ownership.

check_boxKey Events

• Director Converts Preferred Stock

  Director Stephen M. Hahn converted 44.763 shares of Series B Preferred Stock into 44,763 shares of common stock.

• Significant Common Stock Holdings

  The acquired common stock is valued at $619,968, representing over 3% of the company's market capitalization.

• Post-Merger Capital Restructuring

  This conversion follows the recent acquisition of Faeth Therapeutics and associated recapitalization efforts, aligning the director's equity more directly with common shareholders.

• Option Grant Received

  The director also received a grant of 25,000 stock options, vesting over a three-year period.

auto_awesomeAnalysis

Director Stephen M. Hahn converted Series B Preferred Stock, which he received as part of the recent Faeth Therapeutics merger, into common stock. This conversion, valued at $619,968, significantly increases his direct common stock holdings by over 3% of the company's market capitalization. This action represents a material step in aligning his equity interests with common shareholders following the major recapitalization event and the integration of the acquired entity.